Clinical trials: psoriasis
Psoriasis
Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting
Study is not recruiting and using secondary data sources only
- Trial name
- NCT04799990
- Testing
- Risankizumab, Comparator 1, Comparator 2
- Sponsor
- AbbVie
Chronic Plaque Psoriasis
Raptiva in Palm and Sole Psoriasis
The primary purpose of the study is to evaluate the safety and efficacy of Raptiva® compared to placebo in controlling moderate to severe chronic plaque psoriasis involving palms and/or soles scoring Palmo-plantar Pustular…
- Trial name
- NCT00972543
- Testing
- Efalizumab (Raptiva)
- Volunteers
- 6 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriatic Arthritis
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had…
- Trial name
- NCT04908189
- Testing
- Deucravacitinib, Apremilast
- Where
- 138 sites in United States, Argentina and 16 more
- Volunteers
- 729 people
- Sponsor
- Bristol-Myers Squibb
Atopic Dermatitis, Psoriasis
Analytical Validation of Wrist-Based Assessment of Nocturnal Scratch in Atopic Dermatitis and Psoriasis
Pruritis is a common symptom in patients with atopic dermatitis and psoriasis. Patients with atopic dermatitis and psoriasis often report pruritis-associated sleep impairments and scratching behaviors during nighttime and the…
- Trial name
- DECODE-Scratch (NCT06448689)
- Where
- France
- Volunteers
- 90 people
- Sponsor
- ActiGraph L.L.C
Self-Management, Behavior
Development and Feasibility of a Nurse-led Person-centered Education Program
Background Psoriasis is a chronic inflammatory skin disease causing reduced quality of life. Psoriasis patients are often insufficiently informed about their disease with its treatment possibilities leading to non-adherence of…
- Conditions
- Self-Management, Behavior, Patient Empowerment
- Trial name
- PsoEd (NCT05715190)
- Testing
- Education
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- School of Health Sciences Geneva
Psoriasis, Plaque Psoriasis
Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients
This is a randomized, double-blind, placebo-controlled, multicenter clinical trial conducted in China. The study aims to evaluate the efficacy and safety of metformin combined with secukinumab in the treatment of…
- Conditions
- Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis, Overweight , Obesity
- Trial name
- NCT07485764
- Testing
- Secukinumab 300mg s.c., Metformin
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Psoriasis
MAP Study: Methotrexate and Adalimumab in Psoriasis
Assess the efficacy and safety of ADA compared to ADA/MTX in patient with Psoriasis. Compare Anti-ADA antibody formation and serum ADA levels in patients on ADA compared with those on combination ADA and MTX.
- Trial name
- MAP (NCT03217734)
- Testing
- Adalimumab, Methotrexate
- Where
- 4 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jeffrey J Crowley MD
Scalp Psoriasis
To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis
This is a phase III, randomized, double-blind, placebo-controlled, parallel- group, multiple-site study to evaluate the therapeutic equivalence of generic calcipotriene and betamethasone dipropionate topical suspension…
- Trial name
- NCT03331523
- Testing
- Calcipotriene/Betamethasone Dipropionate, Taclonex®
- Where
- 31 sites in United States
- Volunteers
- 643 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Psoriatic Arthritis
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).
- Trial name
- NCT06671496
- Testing
- Zasocitinib
- Where
- 120 sites in United States, Argentina and 10 more
- Volunteers
- 601 people
- Sponsor
- Takeda
Psoriatic Arthritis
Efficacy and Safety of Fecal Microbiota Transplantation in Peripheral Psoriatic Arthritis
An abnormal intestinal microbiota may be the mediator of the common inflammatory pathways seen in psoriatic arthritis. This study will explore clinical aspects associated with modifying the intestinal microbiota by infusing fecal…
- Trial name
- FLORA (NCT03058900)
- Testing
- Fecal microbiota transplantation (FMT), Methotrexate (MTX)
- Where
- 2 sites in Denmark
- Volunteers
- 31 people
- Sponsor
- Odense University Hospital
Chronic Plaque Psoriasis
Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis
Loading dose, four arm, double-blind, parallel group, placebo-controlled study comparing single and multiple doses of AIN457 to placebo in patients with a diagnosis of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00805480
- Testing
- AIN457
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Micellar Paclitaxel to Treat Severe Psoriasis
This study will evaluate the safety and effectiveness of micellar paclitaxel for treating severe psoriasis. Paclitaxel in another formulation (Taxol) is approved by the Food and Drug Administration for use in patients with…
- Trial name
- NCT00006276
- Testing
- Micellar Paclitaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Primary Immunodeficiency, Psoriasis
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
Background: The immune system is the part of the body that fights infection. Some people have immune deficiencies that cause skin rashes, make them get sick often with infections, or make it difficult for their skin to heal.
- Conditions
- Primary Immunodeficiency, Psoriasis, Atopic Dermatitis, Immune-mediated Diseases
- Trial name
- NCT04864886
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)
The purpose of the study is to evaluate the ability of subjects with moderate to severe chronic plaque psoriasis (PSO) to safely and effectively self-inject bimekizumab at study start and 8 weeks after training in self-injection…
- Trial name
- NCT03766685
- Testing
- Bimekizumab
- Where
- 39 sites in United States, Canada
- Volunteers
- 172 people
- Sponsor
- UCB Biopharma SRL
Plaque Psoriasis
A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis
To compare disease activity, as measured by PASI score, of three MEDI-507 dosing (injection)regimens vs. placebo.
- Trial name
- NCT00540618
- Testing
- MEDI-507
- Where
- 43 sites in United States, Canada
- Volunteers
- 420 people
- Sponsor
- MedImmune LLC
Psoriatic Arthritis
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
The main purpose of this study is to evaluate the safety and long-term efficacy of ixekizumab compared to placebo in participants with active psoriatic arthritis.
- Trial name
- SPIRIT P3 (NCT02584855)
- Testing
- Ixekizumab
- Where
- 106 sites in United States, Bulgaria and 10 more
- Volunteers
- 394 people
- Sponsor
- Eli Lilly and Company
Psoriasis Vulgaris
Oral and Topical Phytocannabinoids for Psoriasis
Psoriasis is a chronic inflammatory skin disease that affects approximately 2% of the global population and is frequently associated with psychiatric comorbidities such as anxiety and depression.
- Trial name
- CBDermis (NCT07839455)
- Testing
- Oral Cannabis Extract, Topical cannabis cream
- Where
- Brazil
- Volunteers
- 37 people
- Sponsor
- Federal University of Latin American Integration
Plaque Psoriasis
RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization
RESTORE is an observational, open-label, multi-center, prospective, study enrolling Raptiva® (efalizumab) treated patients with moderate to severe chronic plaque psoriasis.
- Trial name
- RESTORE (NCT00402818)
- Where
- Canada
- Volunteers
- 294 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Palmoplantar Psoriasis, Eczema
Dermoscopy and UVFD in Differentiating Palmoplantar Psoriasis and Palmoplantar Eczema
Palmoplantar psoriasis and palmoplantar eczema are chronic inflammatory skin diseases that may show similar findings on the palms and soles, such as redness, scaling, thickening of the skin, fissures, itching, and burning.
- Trial name
- NCT07626697
- Where
- Turkey (Türkiye)
- Volunteers
- 81 people
- Sponsor
- Istanbul Training and Research Hospital
Chronic Plaque Psoriasis
Narrowband UVB Phototherapy in the Treatment of Psoriasis Vulgaris
Ultra-violet light B (UVB) therapy has been used by dermatologists to treat psoriasis for decades. Only a few studies have begun to dissect the mechanism of how NB-UVB therapy causes lesion resolution.
- Trial name
- NCT00844363
- Testing
- NB-UVB
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rockefeller University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.